Keyword: Patent Trial and Appeal Board
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.
Biogen has prevailed in a patent squabble with Forward Pharma over Tecfidera, but can the decision actually help the Big Biotech dodge generic rivals?
Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.